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Abstract
Thyroid C-cells produce calcitonin (CT), a hypocalcemic hormone, that acts as an inhibitor of bone resorption. In
this study, we investigated the effects of tamoxifen (TAM) as a selective estrogen receptor modulator on
thyroid C-cells, trabecular bone and biochemical markers of bone metabolism in an animal model of androgen
deficiency, represented by middle-aged orchidectomized (Orx) rats. Fifteen-month-old male Wistar rats were
divided into: Orx and sham-operated (SO) groups. Rats from one Orx group were injected subcutaneously with
TAM citrate (Orx + TAM; 0.3 mg kg1 b.w.), while the rats from SO and a second Orx group received vehicle
alone, once a day for 3 weeks. The peroxidase–antiperoxidase method was applied for localization of CT in C-
cells. Thyroid C-cells were morphometrically and ultrastructurally analyzed. An ImageJ image-processing
program was used to measure bone histomorphometric parameters. Blood serum samples were analyzed for
CT, osteocalcin (OC), calcium (Ca2+) and phosphorus (P). Urinary Ca2+ concentrations were measured. TAM
treatment significantly increased thyroid C-cell volume (Vc) and serum CT when compared with vehicle-treated
Orx rats. Analysis of trabecular microarchitecture of the tibia showed that administration of TAM significantly
increased cancellous bone area, trabecular thickness and trabecular number, whereas trabecular separation was
significantly decreased compared with vehicle-treated Orx rats. Serum OC and urinary Ca2+ concentrations were
significantly lower in comparison with the control Orx group. These results indicate that in our rat model of
androgen deficiency, TAM stimulated calcitonin-producing thyroid C-cells and increased trabecular bone mass.
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Introduction
Osteoporosis is a disease characterized by low bone mass
and microarchitectural deterioration of bone tissue. Age-
related bone loss due to gonadal steroid deficiency is
greater in women than in men (Khosla & Riggs, 2005). Anti-
resorptive drugs used in the treatment of osteoporosis
include bisphosphonates, hormone replacement therapy,
selective estrogen-receptor modulators (SERMs) and the
peptide hormone calcitonin (CT).
Natural CT produced by thyroid C-cells (Zaidi et al. 2002)
acts as an acute hypocalcemic hormone and also as a potent
inhibitor of osteoclastic bone resorption (Chambers & Mag-
nus, 1982). The function of thyroid C-cells and correspond-
ing level of plasma CT are influenced by aging, including
age-related sex hormonal changes. Unlike humans, in which
gonadal steroids, plasma CT levels and number of thyroid
C-cells decline with age, physiological hyperplasia of C-cells
and hypercalcitoninemia were observed in old rats (Delver-
dier et al. 1990; Sekulic et al. 1998; Lu et al. 2000).
In the state of gonadal steroid deficiency, an appropriate
estrogen or testosterone administration has bone-protec-
tive effects and stimulates the activity of CT-producing thy-
roid C-cells in rats (Catherwood et al. 1983; Yamazaki &
Kinoshita, 1986; Filipovic et al. 2003, 2013). Clinical
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investigations indicate that, together with the lack of
testosterone, estrogen deficiency plays an important role in
age-related bone loss in elderly men (Slemenda et al. 1997).
However, exposure to estrogen increases the risk of
hormone-associated cancers, such as uterine or breast can-
cers in women and men (Anelli et al. 1994; Colditz et al.
1995; Grady et al. 1995). Moreover, the use of exogenous
testosterone in men is associated with the development of
prostate cancer (Gaylis et al. 2005) and possibly with breast
cancer (Thomas et al. 2008).
Because the effects of estrogens in target tissues are medi-
ated by specific estrogen receptors (ERs; Kuiper et al. 1996),
the use of SERMs that lack the adverse effects of estrogenmay
be beneficial for treatment of age-related bone loss, with little
risk of breast growth in elderly women and men. SERMs may
have estrogenic and anti-estrogenic activities in different tis-
sues (Gottardis & Jordan, 1987; Turner et al. 1988).
Tamoxifen (TAM) is a SERM used for treatment of
ER-positive breast cancer in both women and men (Ribeiro,
1983; Osborne, 1998). Laboratory studies show that TAM
acts as an estrogen in bone, but also as an anti-estrogen in
mammary tissue (Gottardis & Jordan, 1987; Turner et al.
1988). Clinical and experimental data related to the effects
of TAM mainly concern the female sex. There is little infor-
mation on the action of TAM in men and male animals,
despite the fact that TAM is used to treat breast cancer in
men (Anelli et al. 1994). Thus, in this study we have investi-
gated the effects of TAM as a potent inhibitor of bone
resorption on thyroid C-cells and trabecular bone micro-
architecture, by using orchidectomized (Orx) male rats as a
suitable animal model for male osteoporosis.
Materials and methods
Animals and experimental groups
Twenty-four 15-month-old male Wistar rats, bred at the Institute
for Biological Research ‘Sinisa Stankovic’, University of Belgrade,
Serbia, were maintained under constant laboratory conditions
(room temperature 22 °C, 12 h/12 h light/dark cycle), with free
access to food and water. Sixteen rats were randomly bilaterally
Orx under ketamine anesthesia (intramuscularly injected at a dose
of 15 mg kg1 body weight). Eight rats were sham-operated (SO).
Two weeks after the surgery the rats were divided into three
groups (eight rats per group). One Orx group was injected subcuta-
neously (s.c.) with TAM citrate (Sigma-Aldrich, St Louis, MO, USA) at
a dose of 0.3 mg kg1 b.w. daily for 3 weeks. This dose of TAM was
used to mimic the standard dose of TAM used for patients with
breast cancer (Makris et al. 1998). The SO and other Orx rats were
s.c. administrated the same volume of vehicle alone (controls). Urine
was collected for 24 h before death. Sera were separated from
trunk blood after decapitation and stored at 70 °C until analyzed
biochemically. All animal procedures were in compliance with the
EEC Directive (2010/63/EU) on the protection of animals used for
experimental and other scientific purposes, and were approved by
the Ethical Committee for the Use of Laboratory Animals of the
Institute for Biological Research, ‘Sinisa Stankovic’ University of Bel-
grade, Serbia.
Immunohistohemical stains
Thyroid lobes were isolated and fixed in Bouin’s solution, embed-
ded in paraplast, and cut into 5-lm-thick longitudinal sections.
Deparaffinized sections were stained immunohistochemically with
rabbit antisera directed against human CT (Dakopatts, Copenhagen,
Denmark; 1 : 500), using the peroxidase–antiperoxidase method.
Stereological analysis of CT-labeled thyroid C-cells
Immunocytochemically stained C-cells in the central part of each rat
thyroid were stereologically analyzed by a point-counting method
described by Filipovic et al. (2007), using a M42 multipurpose test
grid inserted into the ocular of a Zeiss light microscope (Jena, Ger-
many). The cell volume of thyroid C-cells (Vc) and their volume den-
sity (VV) were estimated on 50 test fields per section at 1000
9 magnification.
Electron microscopy
Samples of thyroid gland lobes were fixed in 4% glutaraldehyde
solution in 0.1 M phosphate buffer (pH 7.4) for 24 h. Samples were
postfixed in 1% osmium tetroxide dissolved in the same buffer,
dehydrated in a graded series of ethyl alcohol and embedded in
Araldite resin. Ultrathin sections of thyroid gland were stained with
uranyl acetate and lead citrate, and viewed with a transmission
electron microscope (MORGAGNI 268; FEI Company, USA).
Trabecular bone histomorphometry
The right tibiae were cleaned of soft tissue, fixed in Bouin’s solu-
tion, decalcified in 20% ethylenediaminetetraacetic acid disodium
salt (EDTA, pH 7.4), routinely processed and embedded in paraplast.
Longitudinal sections of the proximal tibiae were cut through the
middle part of the bone using a rotation microtome (RM 2125; Le-
ica, Germany) with microtome blades for hard sections (Sakura Fine-
tek, Japan). These 5-lm-thick sections were stained by the Azan
method, as previously described (Filipovic et al. 2007).
An ImageJ public domain image-processing program was used
for histomorphometric measurements on a trabecular area of the
tibia, starting 1 mm below the epiphyseal growth plate. Histo-
morphometry terminology and the calculations used are those
described in the Report of the American Society for Bone and Min-
eral Research Committee Histomorphometry Nomenclature (Parfitt
et al. 1987). The data automatically determined by the image analy-
sis system were used to calculate the cancellous bone area (B.Ar)
and cancellous bone perimeter (Evans et al. 1994). Trabecular thick-
ness (Tb.Th), trabecular number (Tb.N) and trabecular separation
(Tb.Sp) were derived from these parameters as described earlier (Fil-
ipovic et al. 2007).
Biochemical analyses of serum and urine samples
Blood serum was collected for determination of CT, osteocalcin
(OC), calcium (Ca2+) and phosphorus (P) concentrations. Twenty-
four hour urine samples were collected for measurement of Ca2+
concentration. Serum CT levels were assayed immunochemilumino-
metrically (Nichols, USA) using a mouse monoclonal anti-human CT
antibody marker with acridium ester. The luminescence was quanti-
fied with a semi-automated MLA 1 hemiluminescence analyzer
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(Ciba-Corning). A Roche Elecsys 2010 immunoassay analyzer (Roche
Diagnostics GmbH, Mannheim, Germany) was used to quantify
serum OC. Serum Ca2+ and P, and urinary Ca2+ were determined on
a Hitachi 912 analyzer (Roche Diagnostics GmbH).
Statistical analysis
All data were analyzed using STATISTICA 6.0 software (Statsoft, Tulsa,
Oklahoma, USA). The Kolmogorov–Smirnov test was used to deter-
mine potential deviation from normal distribution, followed by
one-way analysis of variance (ANOVA). Duncan’s multiple range test
was employed for post hoc comparisons. Differences between mean
values were considered to be significant at P < 0.05. The data are
presented as means  standard error of the mean (SEM).
Results
Immunohistomorphometric and ultrastructural
assessment of thyroid C-cells
Thyroid C-cells in the SO rats were numerous, large andmainly
occurred in clusters. Their cytoplasm was lightly immuno-
stained for CT (Fig. 1a,b). In Orx rats, C-cells were present in
smaller groups or individually. They were smaller, with stron-
ger immunoreaction to CT compared with C-cells in SO rats
(Fig. 1c,d). After TAM treatment of Orx rats, the C-cells were
larger, with granular lighter immunostaining within the cyto-
plasm than in the vehicle-treated Orx animals (Fig. 1f,g).
The ultrastructure of thyroid C-cells in the SO animals was
predominantly characterized by the presence of granules of
lower electron density. Mitochondria were numerous, oval
and dispersed in the cytoplasm. A well-developed Golgi
complex and long profiles of rough endoplasmic reticulum
were observed (Fig. 2, SO). The relative abundance of high
electron density granules in C-cells of Orx rats was
increased. The cytoplasm contained fewer organelles than
in SO animals (Fig. 2, Orx). After TAM treatment of Orx rats,
the ultrastructure of the C-cells was similar to that of SO rats
and revealed cytoplasm rich in organelles (Fig. 2, Orx +
TAM).
We have previously reported that Orx induces a signifi-
cant decrease in Vc and Vv of thyroid C-cells when com-
pared with SO rats (Filipovic et al. 2007). Treatment of Orx
animals with TAM increased C-cell Vc by 17% (P < 0.05),
with Vv not significantly altered in relation to the values
obtained for control Orx rats. No significant differences in
Vc and Vv of thyroid C-cells were detected between TAM-
treated and SO rats (Fig. 3a,b).
a b
c d
e f
Fig. 1 Calcitonin-producing thyroid C-cells. In
SO animals, C-cells are numerous and large,
with light cytoplasm (a and b). Small groups
or individual, smaller C-cells with darker
cytoplasm in Orx rats (c and d). Large clusters
of C-cells with lighter cytoplasm in Orx rats
treated with TAM (Orx + TAM) (e and f).
Immunoperoxidase staining specific for
calcitonin.
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Histomorphometric assessment of trabecular bone
It has previously been reported that Orx in middle-aged rats
markedly reduces trabecular bone tissues, and decreases
the value of trabecular bone structural parameters, such as
B.Ar, Tb.Th, Tb.N, and increases Tb.Sp of the tibia (Filipovic
et al. 2007). Administration of TAM to Orx rats reversed the
effects of Orx and prevented structural deterioration of tra-
becular bone (Fig. 4, upper). Thus, in Orx rats injection of
TAM increased B.Ar, Tb.Th and Tb.N by 113%, 29% and
26% (P < 0.05), respectively, when compared with the con-
trol Orx group. Tb.Sp was 24% lower (P < 0.05) in the Orx +
TAM group than in the control Orx group. No differences
in bone structural parameters of proximal tibia between
Orx rats treated with TAM and SO animals (Fig. 4, below)
were observed.
Serum and urine parameters
In our previously published work (Filipovic et al. 2007), we
reported that Orx significantly decreases serum CT, Ca2+
and P, and increases OC and urinary Ca2+ concentration.
TAM given to the Orx rats increased serum CT concentra-
tion, which was 44% (P < 0.05) higher than in the control
Orx group, and 34% lower (P < 0.05) compared with the SO
group (Fig. 5a). Administration of TAM decreased serum
OC concentration by 51% (P < 0.05) in comparison with
vehicle-treated Orx rats (Fig. 5b). Furthermore, after TAM
Fig. 2 Ultrastructure of thyroid C-cells in
sham-operated (SO), orchidectomized (Orx)
and Orx rats treated with tamoxifen (Orx +
TAM). G, Golgi complex; GER, granular
endoplasmic reticulum; M, mitochondria; N,
nucleus; sg, secretory granules.
a b
Fig. 3 (a) Cellular volume (Vc) and (b) volume
density (Vv) of CT-immunoreactive thyroid C-
cells. Orx, orchidectomized rats; Orx + TAM,
Orx rats treated with tamoxifen; SO, sham-
operated control. All values are mean  SEM.
#P < 0.05 vs. SO and *P < 0.05 vs. Orx.
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administration, serum Ca2+ and P were 9% and 15% lower
(P < 0.05), respectively, compared with levels detected in SO
rats (Fig. 5c). Urinary Ca2+ concentration in TAM-treated
rats was 71% (P < 0.05) lower than in the control Orx group,
while the decrease of 34% in comparison with SO rats was
not statistically significant (Fig. 5c).
Discussion
Synthetic salmon CT is one of the therapeutic options for
treatment of osteoporosis. This peptide regulates Ca2+ and
P metabolism, and is a powerful physiological inhibitor of
osteoclast activity (Tuck & Datta, 2007). Natural CT is pro-
duced and secreted by thyroid C-cells, and these processes
are influenced by gonadal steroids (Chambers & Magnus,
1982). In our previous papers we have reported that sex ste-
roid deficiency induced by gonadectomy modulated the
structure of CT-producing thyroid C-cells, and diminished
CT secretion both in female and male rats (Filipovic et al.
2003, 2007). In middle-aged male rats, Orx induced
decreases of Vc and Vv of thyroid C-cells, and reduced serum
CT levels (Filipovic et al. 2007). Administration of estradiol
or testosterone to Orx rats stimulated the secretory activity
of thyroid C-cells (Filipovic et al. 2013).
However, although gonadal steroids have a beneficial
effect on bone tissue, estrogens may increase the risk of
developing breast cancer in humans (Colditz et al. 1995),
and promote mammary gland hyperplasia in female and
male rats (Andrews et al. 2002). Therefore, we chose to use
TAM for our study as a non-steroidal anti-estrogen, which is
used as an essential drug for treatment of breast cancer.
This SERM exerts anti-estrogenic effects on the breast but
mimics them on bone (Gottardis & Jordan, 1987; Turner
et al. 1988).
In the present study we have demonstrated that TAM acts
on the CT-producing thyroid C-cells in androgen-deficient
male rats. Thus, TAM treatment significantly increased C-cell
volume when compared with that in Orx rats. Ultrastructur-
al analysis indicated mostly the presence of low electron
density granules and cytoplasm richer in organelles than in
Orx animals. These findings, together with elevated serum
CT levels, suggest that TAM treatment stimulates CT synthe-
sis and secretion from thyroid C-cells. To our knowledge,
this is the first study to examine the effect of TAM adminis-
tration on the structure and function of thyroid C-cells.
However, TAM inhibited proliferation of a tumor cell line
derived from human medullary thyroid carcinoma, a thy-
roid C-cell neoplasm (Yang et al. 1988).
The effect of TAM on thyroid C-cells may be mediated by
ERs, which have been detected in both normal and hyper-
plastic C-cells (Naveh-Many et al. 1992; Blechet et al. 2007).
The earlier report (Greenberg et al. 1986) suggested that
Fig. 4 Upper: histological sections of trabecular bone from proximal tibia metaphysis in sham-operated (SO), orchidectomized (Orx) and Orx rats
treated with tamoxifen (Orx + TAM). The metaphyseal region of the proximal tibia in SO rats contains well-developed blue-stained trabeculae.
After Orx, the trabeculae are markedly attenuated and thinner. In the Orx + TAM animals, trabecular structure, destroyed after Orx, has recovered;
5-lm sections from the center of the specimen; Azan method stain. Below: histomorphometric parameters of bone structure. Cancellous bone
area (B.Ar), trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular separation (Tb.Sp). All values are mean  SEM. #P < 0.05 vs. SO
and *P < 0.05 vs. Orx.
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TAM competitively binds to ERs but does not inhibit estro-
gen-induced CT release. It is possible that by binding to ERs
as an estrogen agonist, TAM could affect thyroid C-cell
activity. In addition, there are possible indirect effects of
TAM on C-cells. Long-term TAM therapy in women with
breast cancer may lead to increased serum dehydroepiand-
rosterone (DHEA) levels (Lum et al. 1997). This sex hormone
precursor can be converted to testosterone by hydroxyster-
oid dehydrogenase action and finally to estradiol under the
influence of P450 aromatase (Labrie et al. 2005). Estradiol
and testosterone produced by conversion of DHEA may
bind to their receptors on C-cells affecting their activity.
Although ERs were detected in normal C-cells (Naveh-Many
et al. 1992), we cannot be sure that androgen receptors
(ARs) are functional in these cells. ARs were found in hyper-
plastic C-cells and medullary thyroid carcinoma (Zhai et al.
2003; Blechet et al. 2007). However, this does not exclude
the possibility of aromatization of testosterone to estradiol
and subsequent action through ERs in C-cells (Simpson &
Dowsett, 2002).
In our study, TAM treatment increased the activity of thy-
roid C-cells, but these findings cannot illuminate the exact
mechanism(s) of TAM action on these cells. Therefore,
further research is needed to clarify the way in which this
SERMs act on thyroid C-cells.
Patients with breast cancer have an increased risk of oste-
oporosis due to various factors, such as advanced age, che-
motherapy or aromatase inhibitor therapy. Due to the high
rate of ER positivity in male breast cancer, TAM therapy has
been used in men (Anelli et al. 1994). Therefore, we have
examined the effect of TAM treatment on trabecular bone
in Orx rats as an excellent animal model of androgen defi-
ciency (Vanderschueren et al. 1992). Our earlier published
results demonstrate that androgen deficiency induced by
Orx markedly decreases trabecular bone mass in male mid-
dle-aged rats (Filipovic et al. 2007). In the current study,
treatment of Orx rats with TAM significantly improved
bone structural parameters, such as B.Ar, Tb.Th and Tb.N,
whereas Tb.Sp was markedly lower than in the control Orx
rats. We also obtained significant decreases in serum OC
and urinary Ca2+ excretion after TAM treatment. These find-
ings suggest that TAM is an effective anti-resorptive agent
that prevents trabecular bone loss and decreases bone turn-
over markers in our model. Other studies also demonstrated
that TAM prevents bone loss in androgen-deficient male
mice and rats (Broulik, 2000; Fitts et al. 2004), as well as in
a
c
b
Fig. 5 (a) Serum calcitonin (CT)
concentration (ng L1). (b) Serum osteocalcin
(OC) concentration (ng mL1). (c) Serum
calcium (Ca2+), serum phosphorus (P) and
urine calcium (uCa) concentration
(mmol L1). Orx, orchidectomized rats; Orx +
TAM, Orx rats treated with tamoxifen; SO,
sham-operated control. All values are mean 
SEM. #P < 0.05 vs. SO and *P < 0.05 vs. Orx.
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ovariectomized rats (Turner et al. 1988) and postmeno-
pausal women (Powles et al. 1996).
The mechanisms by which TAM exerts its effects on bone
may involve ERs. Both ER-a and ER-b isoforms are present in
osteoblasts and osteoclasts (Eriksen et al. 1988; Bord et al.
2001). As an estrogen agonist, TAM binds to an ER and
mimics the effects of estrogen in bone cells. It has been sug-
gested that in vivo in rats, TAM prevents the increase of
osteoclast number and activity (Turner et al. 1988). As con-
firmation that the ER-mediated mechanism is involved in
the direct inhibitory effect of TAM on osteoclast differentia-
tion, an in vitro study showed that the anti-estrogen ICI 182
780 can prevent inhibition of differentiation of these cells
(Michael et al. 2007). In addition to a direct effect on osteo-
clasts, TAM may also inhibit osteoclastogenesis by acting as
an estrogen agonist on osteoprotegerin production in os-
teoblasts (Michael et al. 2007).
The significant increase in serum CT following TAM treat-
ment, detected in the current study, suggests a possible
indirect mechanism of TAM action on bone through
increased activity of CT-producing thyroid C-cells. Namely,
as a potent inhibitor of osteoclastic bone resorption, CT
affects osteoclasts directly by binding to CT receptors
located on these cells (Nicholson et al. 1986), reducing their
number and mobility (Zaidi et al. 1990; Gao & Yamaguchi,
1999). Also, CT increases osteoblast proliferation and the
activity of alkaline phosphatase. This action of CT is, at least
in part, mediated via CT receptors located on osteoblasts
(Villa et al. 2003).
In conclusion, the present study is the first to provide evi-
dence that TAM stimulates thyroid C-cell activity and CT
production in Orx male rats. Also, as an estrogen agonist,
TAM prevented trabecular bone loss in our animal model of
androgen deficiency. In addition to its known protective
role in breast cancer, TAM treatment may have the addi-
tional beneficial effect on bone in male patients with breast
cancer. Taken together, our results suggest that TAM may
also affect bone tissue by regulating endogenous CT, pro-
duced by thyroid C-cells.
Acknowledgements
This work was supported by the Ministry of Education, Science and
Technological Development of the Republic of Serbia, Grant No.
173009. The authors wish to express their gratitude to Dr Anna Nik-
olic, PhD for language correction of the manuscript.
References
Andrews P, Freyberger A, Hartmann E, et al. (2002) Sensitive detec-
tion of the endocrine effects of the estrogen analogue ethinylest-
radiol using a modified enhanced subacute rat study protocol
(OECD Test Guideline no. 407). Arch Toxicol 76, 194–202.
Anelli TF, Anelli A, Tran KN, et al. (1994) Tamoxifen administra-
tion is associated with a high rate of treatment-limiting symp-
toms in male breast cancer patients. Cancer 74, 74–77.
Blechet C, Lecomte P, De Calan L, et al. (2007) Expression of sex
steroid hormone receptors in C cell hyperplasia and medullary
thyroid carcinoma. Virchows Arch 450, 433–439.
Bord S, Horner A, Beavan S, et al. (2001) Estrogen receptors
alpha and beta are differentially expressed in developing
human bone. J Clin Endocrinol Metab 86, 2309–2314.
Broulik PD (2000) Tamoxifen prevents bone loss in castrated
male mice. Horm Metab Res 32, 181–184.
Catherwood BD, Onishi T, Deftos LJ (1983) Effect of estrogens
and phosphorus depletion on plasma calcitonin in the rat. Cal-
cif Tissue Int 35, 502–507.
Chambers TJ, Magnus CJ (1982) Calcitonin alters behaviour of
isolated osteoclasts. J Pathol 136, 27–39.
Colditz GA, Hankinson SE, Hunter DJ, et al. (1995) The use of
estrogens and progestins and the risk of breast cancer in post-
menopausal women. N Engl J Med 322, 1589–1593.
Delverdier M, Cabanie P, Roome N, et al. (1990) Quantitative
evaluation by immunocytochemistry of the age-related varia-
tions in thyroid C cells in the rat. Acta Anat (Basel) 138, 182–
184.
Eriksen EF, Colvard DS, Berg NJ, et al. (1988) Evidence of estro-
gen receptors in normal human osteoblast-like cells. Science
241, 84–86.
Evans G, Bryant HU, Magee D, et al. (1994) The effects of ra-
loxifene on tibia histomorphometry in ovariectomized rats.
Endocrinology 134, 2283–2288.
Filipovic B, Sosic-Jurjevic B, Nestorovic N, et al. (2003) The thy-
roid C cells of ovariectomized rats treated with estradiol. His-
tochem Cell Biol 120, 409–414.
Filipovic B, Sosic-Jurjevic B, Ajdzanovic V, et al. (2007) The
effect of orchidectomy on thyroid C cells and bone histo-
morphometry in middle-aged rats. Histochem Cell Biol 128,
153–159.
Filipovic B, Sosic-Jurjevic B, Ajdzanovic V, et al. (2013) The
effects of sex steroids on thyroid C cells and trabecular bone
structure in the rat model of male osteoporosis. J Anat 222,
313–320.
Fitts JM, Klein RM, Powers CA (2004) Comparison of tamoxifen
and testosterone propionate in male rats: differential preven-
tion of orchidectomy effects on sex organs, bone mass,
growth, and the growth hormone-IGF-I axis. J Androl 25, 523–
534.
Gao YH, Yamaguchi M (1999) Suppressive effect of genistein on
rat bone osteoclasts: apoptosis is induced through Ca2+ signal-
ing. Biol Pharm Bull 22, 805–809.
Gaylis FD, Lin DW, Ignatoff JM, et al. (2005) Prostate cancer in
men using testosterone supplementation. J Urol 174, 534–538.
Gottardis MM, Jordan VC (1987) Antitumor actions of keoxifene
and tamoxifen in the N-nitrosomethylurea-induced rat mam-
mary carcinoma model. Cancer Res 47, 4020–4024.
Grady D, Gebretsadik T, Kerlikowske K, et al. (1995) Hormone
replacement therapy and endometrial cancer risk: a meta-
analyses. Obstet Gynecol 85, 304–313.
Greenberg C, Kukreja SC, Bowser EN, et al. (1986) Effects of
estradiol and progesterone on calcitonin secretion. Endocri-
nology 118, 2594–2598.
Khosla S, Riggs BL (2005) Pathophysiology of age-related bone
loss and osteoporosis. Endocrinol Metab Clin North Am 34,
1015–1030.
Kuiper GG, Enmark E, Pelto-Huikko M, et al. (1996) Cloning of a
novel receptor expressed in rat prostate and ovary. Proc Natl
Acad Sci USA 93, 5925–5930.
© 2015 Anatomical Society
Tamoxifen actions on C-cells and bone tissue, B. Filipovic et al. 495
Labrie F, Luu-The V, Belanger A, et al. (2005) Is dehydroepiand-
rosterone a hormone? J Endocrinol 187, 169–196.
Lu CC, Tsai SC, Chien EJ, et al. (2000) Age-related differences in
the secretion of calcitonin in male rats. Metabolism 49, 253–
258.
Lum SS, Woltering EA, Fletcher WS, et al. (1997) Changes in
serum estrogen levels in women during tamoxifen therapy.
Am J Surg 173, 399–402.
Makris A, Powles TJ, Allred DC, et al. (1998) Changes in hor-
mone receptors and proliferation markers in tamoxifen trea-
ted breast cancer patients and the relationship with response.
Breast Cancer Res Treat 48, 11–20.
Michael H, H€ark€onen PL, Kangas L, et al. (2007) Differential
effects of selective oestrogen receptor modulators (SERMs)
tamoxifen, ospemifene and raloxifene on human osteoclasts
in vitro. Br J Pharmacol 15, 384–395.
Naveh-Many T, Almogi G, Livni N, et al. (1992) Estrogen recep-
tors and biologic response in rat parathyroid tissue and C
cells. J Clin Invest 90, 2434–2438.
Nicholson CG, Mosley JM, Sexton PM, et al. (1986) Abundant
calcitonin receptors in isolated rat osteoclasts. J Clin Invest 78,
355–360.
Osborne CK (1998) Tamoxifen in the treatment of breast cancer.
N Engl J Med 339, 1609–1618.
Parfitt AM, Drezner MK, Glorieux FH, et al. (1987) Bone histo-
morphometry: standardization of nomenclature, symbols, and
units. J Bone Miner Res 2, 595–610.
Powles TJ, Hickish T, Kanis JA, et al. (1996) Effect of tamoxifen
on bone mineral density measured by dual-energy x-ray
absorptiometry in healthy premenopausal and postmeno-
pausal women. J Clin Oncol 14, 78–84.
Ribeiro GG (1983) Tamoxifen in the treatment of male breast
carcinoma. Clin Radiol 34, 625–628.
Sekulic M, Lovren M, Milossevic V, et al. (1998) Thyroid C cells
of middle-aged rats treated with estradiol or calcium. Histo-
chem Cell Biol 109, 257–262.
Simpson ER, Dowsett M (2002) Aromatase and its inhibitors: sig-
nificance for breast cancer therapy. Recent Prog Horm Res 57,
317–338.
Slemenda CW, Longcope C, Zhou L, et al. (1997) Sex steroids
and bone mass in older men. J Clin Invest 100, 1755–1759.
Thomas SR, Evans PJ, Holland PA, et al. (2008) Invasive breast
cancer after initiation of testosterone replacement therapy in a
man – a warning to endocrinologists. Endocr Pract 14, 201–203.
Tuck SP, Datta HK (2007) Osteoporosis in the aging male: treat-
ment options. Clin Interv Aging 2, 521–536.
Turner RT, Wakley GK, Hannon KS, et al. (1988) Tamoxifen inhib-
its osteoclast-mediated resorption of trabecular bone in ovar-
ian hormone-deficient rats. Endocrinology 122, 1146–1150.
Vanderschueren D, Van Herck E, Suiker AMH, et al. (1992) Bone
and mineral metabolism in aged male rats: short- and long-
term effects of androgen deficiency. Endocrinology 130, 2906–
2916.
Villa I, Dal Fiume C, Maestroni A, et al. (2003) Human osteo-
blast-like cell proliferation induced by calcitonin-related pep-
tides involves PKC activity. Am J Physiol Endocrinol Metab
284, E627–E633.
Yamazaki I, Kinoshita M (1986) Calcitonin secreting property of
ipriflavone in the presence of estrogen. Life Sci 38, 535–1541.
Yang K, Pearson CE, Samaan NA (1988) Estrogen receptor and
hormone responsiveness of medullary thyroid carcinoma cells
in continuous culture. Cancer Res 48, 2760–2763.
Zaidi M, Datta HK, Moonga BS, et al. (1990) Evidence that the
action of calcitonin on rat osteoclasts is mediated by two G
proteins acting via separate post-receptor pathways. J Endocri-
nol 126, 473–481.
Zaidi M, Inzerillo AM, Moonga BS, et al. (2002) Forty years of
calcitonin – where are we now? A tribute to the work of Iain
Macintyre, FRS. Bone 30, 655–663.
Zhai QH, Ruebel K, Thompson GB, et al. (2003) Androgen recep-
tor expression in C-cells and in medullary thyroid carcinoma.
Endocr Pathol 14, 159–165.
© 2015 Anatomical Society
Tamoxifen actions on C-cells and bone tissue, B. Filipovic et al.496
